Associated Papers
Oncogenic composite mutations can be predicted by co-mutations and their chromosomal location.
Küçükosmanoglu A et al.
Molecular Oncology, 2024
38757376 (PubMed )
Supplement: MOL2-18-2407-s001.xlsx › 1E_Excluded_datasets
BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression.
Sigarteu Chindris AM et al.
Frontiers in Endocrinology, 2024
39717106 (PubMed )
Supplement: Table8.xlsx › S_Tab._8_TCGA
Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer.
Serebriiskii IG et al.
Npj Genomic Medicine, 2023
38001126 (PubMed )
Supplement: 41525_2023_384_MOESM1_ESM.xlsx › Table_S6
Recapitulating thyroid cancer histotypes through engineering embryonic stem cells.
Veschi V et al.
Nature Communications, 2023
36906579 (PubMed )
Supplement: 41467_2023_36922_MOESM6_ESM.zip › 356656_2_data_0_rq37ls.xlsx › Figure_2f
Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.
Yi Q et al.
Frontiers in Bioengineering and Biotechnology, 2022
35910024 (PubMed )
Supplement: Table2.XLSX › table
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
34630336 (PubMed )
Supplement: Table_1.xlsx › Tab3
Select a paper to view details